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Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, hereditary disease of the skin, which 
manifests as skin fragility, widespread bulla, and erosions that heal with significant scarring and 
contracture. This condition is the result of a COL7A1 gene mutation that encodes Type VII collagen. 
Patients with RDEB are at increased risk for the development of cutaneous squamous cell carcinoma 
(SCC).1 The first-line treatment for SCC in RDEB is surgery, but the postsurgical defect poses a 
challenge for repair given the recurrent blistering and erosions. The skin defect has traditionally been left 
to heal by secondary intention or repaired with split or full-thickness skin grafts,2 which have the 
disadvantages of limited normal skin for grafting and the potential for prolonged healing of the harvest 
site. We introduce the porcine small intestinal submucosa (SIS) matrix as a novel reconstructive option 
for the repair of surgical defects or nonsurgical wounds in patients with RDEB.  
Small intestinal submucosa matrix has been successfully used 17 times on the extremities of 2 
patients with RDEB in our clinic, each time after Mohs micrographic surgery (MMS) for the 
treatment of an SCC. Patient 1, a 46-year-old man with Hallopeau-Siemens type RDEB, was treated 
12 times. Patient 2, a 43-year-old woman, was treated 5 times. After an average of 2.0 stages of 




MMS, postsurgical defects ranged in size from 5 to 62 cm2 (mean of 16.8 +/- 15.7 cm2). Each defect 
was allowed to heal by secondary intention facilitated by the placement of porcine SIS matrix in the 
wound bed, adhered to surrounding skin using steristrips (Figure 1), and covered in a thin layer of 
petrolatum ointment and a pressure dressing. A bed of granulation tissue covered each defect at 4 
weeks, and all wounds healed in an average of 6.0 weeks (range 5.5-7.0 weeks). Furthermore, none of 
the defects treated with SIS resulted in chronic wounds, which is commonly observed in RDEB 
wounds in general.3 Both patients reported good functional and cosmetic outcomes (Figure 1).  
The wound-healing environment in patients with RDEB is unfavorable. Therefore, a product that mimics 
the native extracellular matrix (ECM) and provides scaffolding for the ingrowth of cells could be highly 
beneficial. The porcine SIS matrix (OASIS and OASIS Ultra; Cook Biotech Inc., West Lafayette, IN) we 
used is especially appealing for patients with RDEB because it interacts with the native epidermis and 
leads to accelerated regeneration of basement membrane components including Type VII collagen,4 the 
same protein that is dysfunctional or absent in RDEB. We postulate this mechanism along with 
providing an intact ECM in the wound is likely responsible for the increased integrity (stabilization of 
anchoring fibrils) and accelerated healing of the skin in patients with mutated or absent Type VII 
collagen treated with porcine SIS matrix. In addition, the SIS matrix contains other important 
components found in the human dermis such as elastin, glycosaminoglycans, glycoproteins, 
proteoglycans, fibroblast growth factor, and transforming growth factor [beta]. Furthermore, SIS matrix 
is easy to apply as described by Cazzell and colleagues.5  
The porcine SIS matrix is an effective alternative reconstruction option for patients with RDEB. It is 
ideal for these patients because it enhances regeneration of Type VII collagen through interaction with 
the epidermis and avoids further manipulation of their fragile skin. Porcine SIS matrix has utility in 
healing wounds in patients with RDEB and should be considered as a viable option for treatment of 
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Figure 1. RDEB patient underwent Mohs micrographic surgery for recurrent SCC on the left elbow. (A) 
The tumor was cleared with 2 stages resulting in a 27-cm2 (6.0 x 4.5-cm) defect down to deep 
subcutaneous tissue. (B) Placement of porcine SIS matrix (Oasis Ultra) in the wound bed. (C) Six-week 
follow-up demonstrates accelerated healing and wound reepithelization. RDEB, recessive dystrophic 
epidermolysis bullosa; SCC, squamous cell carcinoma; SIS, small intestinal submucosa. 
